Ghalib Zahran Al Mawali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ghalib Zahran Al Mawali has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aisha Mahad Al Maashani
Department of Pharmacy and Medical Store, As Sultan Qaboos Hospital, Salalah P.O. Box 98, Oman
1 shared publication - Barbara R. Conway
Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK
1 shared publication - Elizabeth A. Lattyak
Scientific Computing Associates Corp., River Forest, IL 60305, USA
1 shared publication - Faryal Khamis
Infection Diseases Unit, Department of Internal Medicine, Royal Hospital, Muscat, Oman
1 shared publication - Ian Malcolm Gould
Department of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, UK
1 shared publication - José Maria López-Lozano
Biomedical Research Institute of Murcia (IMIB-Arrixaca), 30120 Murcia, Spain
1 shared publication
Latest Publications
- Open Access
- 7 June 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (6) , 775
Identifying Targets for Antibiotic Use for the Management of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in Hospitals—A Multi-Centre Nonlinear Time-Series Study
Solutions are needed to inform antimicrobial stewardship (AMS) regarding balancing the access to effective antimicrobials with the need to control antimicrobial resistance. Theoretical and mathematical models suggest a non-linear relationship between antibiotic use and resistance, indicating the existence of thresholds of antibiotic use beyond which resistance would be triggered. It is anticipated that thresholds may vary across populations depending on host, environment, and organism factors. Further research is needed to evaluate thresholds in antibiotic use for a specific pathogen across different settings. The objective of this study is to identify thresholds of population antibiotic use associated with the incidence of carbapenem-resistant Acinetobacter baumannii (CRAb) across six hospital sites in Oman. The study was an ecological, multi-centre evaluation that involved collecting historical antibiotic use and CRAb incidence over the period from January 2015 to December 2019. By using non-linear time-series analysis, we identified different thresholds in the use of third-generation cephalosporins, piperacillin-tazobactam, aminoglycoside, and fluoroquinolones across participating hospitals. The identification of different thresholds emphasises the need for tailored analysis based on modelling data from each hospital. The determined thresholds can be used to set targets for each hospital AMS, providing a balance between access to these antibiotics versus controlling CRAb incidence.
- 7 June 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (6) , 775
Open AccessIdentifying Targets for Antibiotic Use for the Management of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in Hospitals—A Multi-Centre Nonlinear Time-Series Study
Solutions are needed to inform antimicrobial stewardship (AMS) regarding balancing the access to effective antimicrobials with the need to control antimicrobial resistance. Theoretical and mathematical models suggest a non-linear relationship between antibiotic use and resistance, indicating the existence of thresholds of antibiotic use beyond which resistance would be triggered. It is anticipated that thresholds may vary across populations depending on host, environment, and organism factors. Further research is needed to evaluate thresholds in antibiotic use for a specific pathogen across different settings. The objective of this study is to identify thresholds of population antibiotic use associated with the incidence of carbapenem-resistant Acinetobacter baumannii (CRAb) across six hospital sites in Oman. The study was an ecological, multi-centre evaluation that involved collecting historical antibiotic use and CRAb incidence over the period from January 2015 to December 2019. By using non-linear time-series analysis, we identified different thresholds in the use of third-generation cephalosporins, piperacillin-tazobactam, aminoglycoside, and fluoroquinolones across participating hospitals. The identification of different thresholds emphasises the need for tailored analysis based on modelling data from each hospital. The determined thresholds can be used to set targets for each hospital AMS, providing a balance between access to these antibiotics versus controlling CRAb incidence.